Tasos G. KonidarisChairman of the Board
Mr. Konidaris was appointed to our board of directors in February 2017 and was appointed Chairman in May 2019, having previously served as interim chairman. Mr. Konidaris has served as Executive Vice President and Chief Financial Officer of Alcresta Therapeutics, Inc. since March 2016 and as a senior advisor of Athyrium Capital Management, L.P. since September 2015. Prior to that, he was Senior Vice President and Chief Financial Officer of Ikaria, Inc., a biotherapeutics company, from October 2011 to May 2015. Prior to joining Ikaria, since 2007, Mr. Konidaris served as Senior Vice President and Chief Financial Officer at Dun & Bradstreet (D&B) Corporation, a leading commercial information services company. He was Principal Accounting Officer and led the Global Finance Operations of D&B beginning in 2005. From 2003 to 2005, Mr. Konidaris served as Group Vice President of the Global Pharmaceutical and Global Diversified Products Groups at Schering-Plough Corporation, a pharmaceutical company. Earlier in his career, Mr. Konidaris held senior financial and operational positions of increasing responsibility at the Pharmacia Corporation, Rhone-Poulenc Rorer, Novartis Corporation and Bristol-Myers Squibb Company. Mr. Konidaris currently serves on the boards of Zep, Inc. and Alcresta Therapeutics. Mr. Konidaris served on the board of Pernix Therapeutics Holdings, Inc. from April 2014 to November 2017 and was a director of Delcath Systems Inc. from July 2012 until December 2014. Mr. Konidaris holds an MBA from Drexel University, and a B.S. from Gwynedd Mercy College.
Harlan W. Waksal, M.D.President and Chief Executive Officer
Dr. Waksal has been our President and Chief Executive Officer since August 2014 and was elected to our board of directors in 2013. Prior to joining Kadmon as an employee, Dr. Waksal served as President and Sole Proprietor of Waksal Consulting LLC from 2003 to 2014. From 2011 to 2014, Dr. Waksal served as Executive Vice President, Business and Scientific Affairs at Acasti Pharma, Inc., a publicly traded biopharmaceutical company, and as a consultant to Neptune Technologies & Bioressources, Inc., a publicly traded life sciences company and the parent company of Acasti. Dr. Waksal co-founded ImClone Systems (ImClone) in 1987, a publicly traded biopharmaceutical company acquired by Eli Lilly and Company in 2008. Dr. Waksal served in senior roles at ImClone, including: President (1987 to 1994); Executive Vice President and Chief Operating Officer (1994 to 2002); and President, Chief Executive Officer and Chief Operating Officer (2002 to 2003). Dr. Waksal also served as a Director of ImClone from 1987 to 2005. Dr. Waksal served on the boards of Oberlin College and Sevion Therapeutics through March 2016 and the boards of Acasti and Neptune through February 2016 and July 2015, respectively. Dr. Waksal received his B.A. from Oberlin College and his M.D. from Tufts University School of Medicine. He completed his training in internal medicine at New England Medical Center and in pathology at Kings County Hospital Center in Brooklyn.
Eugene Bauer, M.D.Co-Founder, Director and Chief Medical Officer, Dermira
Dr. Bauer has served as a member of our board of directors since 2010. In 2010, Dr. Bauer co-founded Dermira, a publicly traded specialty biopharmaceutical company, where he serves as Director and Chief Medical Officer. Prior to founding Dermira, Dr. Bauer served as Director, President and Chief Medical Officer of Pelpin, Inc., a publicly traded specialty pharmaceutical company, from 2008 to 2009. Dr. Bauer served as Chief Executive Officer of Neosil, Inc., a specialty pharmaceutical company, from 2006 to 2008, and he co-founded and served as a member of the board of directors at Connetics, a publicly traded specialty pharmaceutical company, from 1990 to 2006. Prior to initiating his career in industry, Dr. Bauer served as Dean of Stanford University School of Medicine and as Chair of the Department of Dermatology at Stanford University School of Medicine from 1995 to 2001. Dr. Bauer is the Lucy Becker Professor Emeritus at Stanford University School of Medicine, a position he has held since 2002. Dr. Bauer was a U.S. National Institutes of Health (NIH)-funded investigator for 25 years and has served on review groups and Councils for the NIH. Dr. Bauer currently serves as a board member for Medgenics, Inc., Cerecor Inc. and First Wave Technologies. He is member of numerous honorific societies, including the National Academy of Medicine. Dr. Bauer received his B.S. from Northwestern University and his M.D. from Northwestern University Medical School.
D. Dixon BoardmanFounder and Chief Executive Officer, Optima Fund Management LLC
Mr. Boardman has served as a member of our board of directors since 2010. Mr. Boardman founded Optima Fund Management LLC, an alternative investment firm, in 1988 and currently serves as Chief Executive Officer. Mr. Boardman is a member of the President’s Council of Memorial Sloan Kettering Cancer Center, where he has also served as Chairman of the Special Projects Committee. He is also a member of the Executive Committee of NewYork Presbyterian-Weill Cornell Council. Mr. Boardman is a Director of Florida Crystals Corporation and an Advisory Board Director of J.C. Bamford Excavators (UK). Mr. Boardman attended McGill University.
David E. Cohen, M.D., MPHCharles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine
Dr. Cohen was appointed to our board of directors in 2019. Dr. Cohen is the Charles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine, where he also serves as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, and Director of Occupational and Environmental Dermatology. Dr. Cohen joined the NYU faculty in 1994 and his work has concentrated on cutaneous allergic and toxic reactions to exogenous and photo-reactive chemicals and the interaction of environmental stressors on the skin. Dr. Cohen has previously served as a lecturer of Environmental Sciences at Columbia University School of Public Health. Dr. Cohen has been a member of the board of directors of Dermira since 2014 and had previously served as a scientific advisor to Dermira since its inception in 2010. Dr. Cohen served on the boards of directors of Vyteris from 2011 to 2012 and Connetics from 2005 until its sale to Stiefel in 2006.
Dr. Cohen is the Past President of the American Dermatological Association, and served as President of the American Contact Dermatitis Society, the Dermatology Section of the New York Academy of Medicine, and the New York Dermatological Association. He served as a founding board member for the American Acne and Rosacea Society, and led the national guidelines of care for individuals with Latex allergy and served on the panel to establish the national guidelines of care for Atopic Dermatitis for the American Academy of Dermatology. Dr. Cohen received his M.D. from the State University of New York at Stony Brook School of Medicine, his MPH at Columbia University, and served as an Intern at Columbia Presbyterian Medical Center, a Dermatology resident from the New York University Medical Center and a resident in Occupational and Environmental Medicine from Columbia University School of Public Health. Dr. Cohen received his B.S. from the City University of New York.
Arthur KirschSenior Advisor and Head of Healthcare, GCA Global
Mr. Kirsch was appointed to our board of directors in 2019. Mr. Kirsch is a Senior Advisor and Head of Healthcare at GCA Global, an investment bank providing strategic M&A, capital markets and private funds advisory services to growth companies and market leaders. From 1994 to 2004, Mr. Kirsch was Global Head of Healthcare Research, with more than 200 companies under coverage, and later served as Head of Capital Markets at Vector Securities, a healthcare investment banking boutique that was later acquired by Prudential Securities. From 1990 to 1993, Mr. Kirsch was Chief Executive Officer of NatWest Markets, currently the investment banking arm of The Royal Bank of Scotland Group. Mr. Kirsch began his career on Wall Street at Drexel Burnham Lambert, where he served as Executive Vice President of the Global Equity Division, a member of the Executive Committee and notably was a #1-ranked Institutional Investor research analyst.
Mr. Kirsch serves on the Board of Directors of Liquidia Technologies, Inc., a public nanotechnology healthcare company, where he is also Chair of the Audit Committee. He previously served on the Board of Directors of Immunomedics, a public biopharmaceutical company, where he also served on the Audit Committee. Mr. Kirsch serves as Chairman of the Board of Directors at Aralez, Inc., a publicly traded biopharmaceutical company, where he is also Chair of the Audit Committee. Mr. Kirsch received his B.A. in Finance from the University of Rhode Island and his MBA in Finance from Bernard M. Baruch College.
Cynthia SchwalmOwner of EIR Advisory LLC
Ms. Schwalm was appointed to our board of directors in 2019. Ms. Schwalm currently serves as the Owner of EIR Advisory LLC, a healthcare-focused strategic partnership and investment company, and as a member of the board of directors at Caladrius Biosciences, G1 Therapeutics and Hikma Pharmaceuticals. Ms. Schwalm served as President and CEO of Ipsen Biopharmaceuticals North America from 2014 through 2017. Prior to joining Ipsen, Ms. Schwalm spent two years in various acting COO and C-suite consulting roles for emerging biotechnology and pharmaceutical companies. Prior to these roles, Ms. Schwalm served as President of Eisai Pharmaceuticals from 2008 to 2010, and as Executive Director from 2003 to 2005 and Vice President from 2005 to 2008 at Amgen, where she ran their oncology business. From 1985 to 2003, Ms. Schwalm held multiple commercial roles, domestically and internationally, at Johnson & Johnson. Ms. Schwalm started her career in oncology and critical care nursing. Ms. Schwalm received her MBA from the Wharton School of the University of Pennsylvania and her B.S.N. from the University of Delaware. Ms. Schwalm is a member of the National Association of Corporate Directors.